PIN9 Antibody

What is PI-9 (SERPINB9) and why is it significant in immunological research?

PI-9 (Proteinase Inhibitor 9), also known as SERPINB9, is a ~42kDa intracellular nucleocytoplasmic serpin expressed primarily in cytotoxic lymphocytes (CTLs), natural killer (NK) cells, monocyte-derived dendritic cells (DCs), and to a lesser extent in B cells and myeloid cells . Its significance in immunological research stems from its role as a potent inhibitor of Granzyme B (GrB), a serine protease that triggers apoptosis when released by cytotoxic T lymphocytes . PI-9 functions as part of a complex that manages cell death pathways, acting as a guardian against excessive cytotoxic actions by the immune system . This protein is upregulated in response to grB production and degranulation, providing a vital self-protection mechanism against premature apoptosis of immune effector cells .

What types of PI-9 antibodies are currently available for research?

Several types of PI-9 antibodies are available for research purposes, including:

Most of these antibodies have been raised against recombinant full-length human SERPINB9 protein or specific epitopes, such as the E9X9Z rabbit mAb that reacts with an epitope surrounding Met280 .

What are the recommended applications for PI-9 antibodies and their optimal working dilutions?

PI-9 antibodies have been validated for multiple applications with specific recommended dilutions:

It's important to optimize these dilutions for your specific experimental system, as expression levels may vary between different cell and tissue types .

How should I validate the specificity of a PI-9 antibody for my research?

Validating antibody specificity is crucial for reliable research outcomes. For PI-9 antibodies, consider implementing these approaches:

• Multiple application testing: Verify antibody performance across different applications (WB, IHC, Flow) to ensure consistent detection .

• Complementary strategies:

  • Use peptide blocking to prevent antibody binding to PI-9

  • Compare results with a different antibody clone targeting the same protein

  • Include positive controls (tissues/cells known to express PI-9, such as NK cells or CTLs)

• Cross-reactivity assessment: Test the antibody on tissues/cells from different species if cross-reactivity is claimed by the manufacturer .

• Molecular weight verification: Confirm that the detected band appears at the expected molecular weight (~42 kDa for PI-9) .

• Negative controls: Include tissues/cells known not to express PI-9 or use PI-9 knockdown/knockout samples if available .

How can I differentiate between active and inactive forms of PI-9 when using antibodies?

Differentiating between active and inactive forms of PI-9 requires careful experimental design:

• Conformation-specific antibodies: Some antibodies may preferentially recognize the native (active) conformation versus the cleaved (inactive) form. Check antibody documentation to determine if it is conformation-specific .

• Sequential immunoprecipitation: Use antibodies targeting different epitopes to potentially distinguish between conformational states.

• Functional assays: Combine antibody detection with functional assays measuring granzyme B inhibition to correlate PI-9 detection with its activity.

• Co-immunoprecipitation: Assess PI-9 interaction with granzyme B, as the active form should form stable complexes with its target protease .

• Gel filtration: Active PI-9 and PI-9:granzyme B complexes will have different molecular weights that can be separated and then detected using the antibody.

What are the key considerations when studying PI-9 expression in tumor samples using immunohistochemistry?

When investigating PI-9 expression in tumor samples via IHC, consider these important factors:

• Fixation and antigen retrieval: PI-9 detection can be sensitive to fixation conditions. Formalin-fixed, paraffin-embedded samples typically require appropriate antigen retrieval methods for optimal staining .

• Subcellular localization: PI-9 can be found in both cytoplasmic and nuclear compartments. Document the distribution pattern observed in your samples .

• Heterogeneity assessment: Tumor samples often display heterogeneous expression. Quantify percentage of positive cells and staining intensity across multiple fields .

• Immune cell infiltration: Since immune cells naturally express PI-9, use double-staining with immune cell markers to differentiate between PI-9 expression in tumor cells versus infiltrating immune cells .

• Clinical correlation: Recent research has identified PI-9/SERPINB9 as a potential immunotherapy target due to its role in tumor cell survival through evasion of apoptosis . Correlate expression patterns with clinical parameters.

What are common issues encountered when using PI-9 antibodies and how can they be resolved?

How should I interpret PI-9 staining patterns in relation to granzyme B expression?

Interpreting PI-9 staining patterns in relation to granzyme B requires careful analysis:

• Co-expression patterns: In immune cells such as CTLs and NK cells, PI-9 and granzyme B should normally co-express as part of the protective mechanism against self-destruction .

• Inverse correlation in tumors: Some tumors may show high PI-9 expression as a mechanism to resist granzyme B-mediated killing by immune cells. Look for inverse relationships between PI-9 expression in tumor cells and evidence of granzyme B-mediated apoptosis .

• Subcellular localization: PI-9 must be present in the same subcellular compartment as granzyme B to inhibit its activity. Compare localization patterns of both proteins .

• Quantitative assessment: Use digital image analysis to quantify relative expression levels of PI-9 and granzyme B across different cell populations within the same sample.

• Functional correlation: Correlate expression patterns with markers of apoptosis or cell death to assess the functional significance of the observed PI-9/granzyme B relationship.

How can AI-based approaches enhance PI-9 antibody development and characterization?

Recent advances in AI technology are transforming antibody development, with implications for PI-9 research:

• AI-designed antibodies: New platforms like RFdiffusion can generate novel antibody blueprints with optimized binding properties. This technology was recently fine-tuned to design human-like antibodies against specific targets, which could be applied to develop more specific PI-9 antibodies .

• Epitope prediction: AI algorithms can predict optimal epitopes for antibody recognition, potentially identifying regions of PI-9 that offer superior specificity or functional relevance.

• Structural modeling: AI-driven protein structure prediction (like AlphaFold) can model PI-9 conformational states, helping design antibodies that recognize specific functional forms.

• Cross-reactivity assessment: Machine learning approaches can predict potential cross-reactivity issues before antibody production, saving time and resources .

• Validation standardization: AI can help develop standardized validation protocols by analyzing patterns across multiple antibody validation datasets, addressing the "antibody characterization crisis" highlighted in recent literature .

What role might PI-9/SERPINB9 antibodies play in emerging cancer immunotherapy research?

PI-9/SERPINB9 antibodies are becoming increasingly important in cancer immunotherapy research:

• Biomarker potential: PI-9 expression has been identified as a potential predictor of immunotherapy response, as tumors expressing high levels may resist immune-mediated killing .

• Therapeutic targeting: Antibodies that can neutralize PI-9's inhibitory function might sensitize tumor cells to granzyme B-mediated apoptosis from cytotoxic immune cells.

• Monitoring treatment response: PI-9 antibodies can help monitor changes in PI-9 expression during immunotherapy, potentially identifying resistance mechanisms.

• Combination therapy development: Understanding PI-9 expression using specific antibodies may guide the development of combination therapies that target both immune checkpoint molecules and resistance mechanisms like PI-9 upregulation.

• CAR-T cell engineering: Knowledge of PI-9's protective role in immune cells, determined through antibody-based research, is informing strategies to engineer more effective CAR-T cells that can overcome tumor resistance mechanisms.